Find Out If You Have a Case

Free, confidential review by Attorney Matthew T. Marin. Prefer to talk? Call (888) 348-2735.

Super Lawyers® 2014–2024CALL 24/7(888) 348-2735

Dupixent Lawsuit — Free, Confidential Case Review

Verdicts and settlements: the honest record

No Dupixent settlement exists yet. Here is how similar drug cases have resolved — and what that history means.

ACTIVE LITIGATION — NO SETTLEMENT. MDL 3180 underway · filing deadlines vary by state.

Were you — or someone you love — diagnosed with CTCL or another T-cell lymphoma after taking Dupixent?

Check if my case qualifiesfree · confidential · takes 2 minutes
I’m not sure of my exact diagnosis →

No documents needed · confidential · an answer either way · no fee unless there is a recovery. Court costs and litigation expenses are advanced by counsel and repaid from the recovery. You are not responsible for court costs or litigation expenses if there is no recovery, unless a court directs otherwise. The attorney’s fee is a percentage of the gross recovery, calculated before expenses are deducted.

Or talk to a person now: (888) 348-2735 — answered 24/7

Stefanie A. Murphy & Matthew T. Marin

Partners

Every Dupixent inquiry gets a personal review — and an honest answer either way, free and without obligation.

Claims are brought against Sanofi and Regeneron, the makers of Dupixent — not against your doctor. Conversations are confidential. Some matters may be referred to other lawyers. No settlement has been reached, and most cases are in their earliest stages; every case must be proven on its own facts. Attorney Advertising.

Lawsuits consolidated in MDL 3180 (D.N.J.) allege that Dupixent (dupilumab) is associated with an increased risk of cutaneous T-cell lymphoma (CTCL) and that the manufacturers failed to warn about it. No court has ruled on these allegations, no settlement exists, and the litigation is in its earliest stages. Published studies report a statistical association — which the study authors themselves note does not establish causation — and the FDA has identified a potential safety signal it is still evaluating; Dupixent’s FDA label does not currently warn about lymphoma. Whether any individual has a claim depends on their medical records and the law of their state.

What does the record actually show as of August 2026?

The consolidated litigation was created on June 4, 2026 and is at its earliest procedural stage. At least 36 cases were docketed in the District of New Jersey as of September 15, 2026. The MDL docket holds 22 entries, the most recent filed September 15, 2026, and the publicly available record shows no leadership appointments, no discovery schedule (discovery is stayed under the June 11, 2026 Initial Procedure Order pending an October 1, 2026 initial management conference), no bellwether selections, no trial date, and no rulings on the merits.

Two procedural rulings have gone against plaintiffs and belong in an honest ledger: the Judicial Panel denied a motion for an expedited hearing in February 2026, and in the transfer order it deferred rather than granted the question of whether non-CTCL T-cell lymphoma cases belong in the MDL, leaving the defendants’ narrower position live. The procedural detail is on our MDL 3180 page.

What will this ledger record when there is something to record?

Each entry will carry the same fields, so entries can be compared rather than admired: the date; the case name and docket number; the court; what was actually decided or agreed; whether it was a jury verdict, a court ruling, or a resolution between parties; whether it favored the plaintiff or the defense; and the docket citation supporting it.

Defense outcomes will be listed the same way plaintiff outcomes are. A ledger that records only good news is not a ledger — it is advertising with a table around it.

Two things will not appear here. Averages, because a handful of early results averaged together describes nothing and misleads everyone. And estimates of what an unresolved case might be worth, because that number does not exist until a jury or an agreement creates it.

Why publish an empty ledger at all?

Because the alternative is what you will find elsewhere: pages promising “estimated settlement amounts” and payout tiers for a litigation that has never produced a single resolved case. Those numbers are not conservative estimates. They are invented, and they are invented for a litigation whose first case was filed less than a year ago. The Dupixent lawsuit overview explains where things actually stand.

An empty ledger costs us something — people search for numbers and we do not have any to give them. It buys something more useful in return. Everything else on this site can be checked against the docket, and you can hold this page up as the test. When there is a verdict, it will appear here. Until then the honest answer is the one at the top of this page.

The same discipline applies to the science: the published studies reporting an association between dupilumab and cutaneous T-cell lymphoma are presented with the authors’ own caveats attached, because those caveats are part of what the research says.

What would have to happen before any of this changes?

In order: the court appoints plaintiff leadership; case management orders organize master pleadings and a discovery schedule; the parties exchange documents and take depositions; both sides retain scientific witnesses and the court decides whether that evidence is admissible; and, if claims survive, representative bellwether cases are tried.

Every one of those stages can also end a litigation rather than advance it. Claims can be dismissed, causation evidence can be excluded, federal preemption can bar state-law failure-to-warn claims, and juries can find for the defense. None of those stages carries a date in this record, and this page does not predict any. If you are trying to work out whether your own records fit the criteria in the meantime, the do I qualify page is the place to look.

What else do people ask about Dupixent verdicts and settlements?